An internal standard for the quantification of stiripentol
Related Products
Unlabeled Version(s)
17781Stiripentol
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Stiripentol-d9

Item No. 28506

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-d3-1-penten-5,5,5-d3-3-ol
CAS Number
1185239-64-8
Molecular Formula
C14H9D9O3
Formula Weight
243.3
Purity
≥99% deuterated forms (d1-d9)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Chloroform: soluble
SMILES
OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])/C=C/C1=CC(OCO2)=C2C=C1
InChi Code
InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+/i1D3,2D3,3D3
InChi Key
IBLNKMRFIPWSOY-QPYRMXHWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $464

    Add
    Product Description

    Stiripentol-d9 is intended for use as an internal standard for the quantification of stiripentol (Item No. 17781) by GC- or LC-MS. Stiripentol is a third-generation antiepileptic compound.1 It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.2 It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.1,3 Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.4 Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Luszczki, J.J. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep. 61(2), 197-216 (2009).

    2. Fisher, J.L. The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology 56(1), 190-197 (2009).

    3. Quilichini, P.P., Chiron, C., Ben-Ari, Y., et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 47(4), 704-716 (2006).

    4. Sada, N., Lee, S., Katsu, T., et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347(6228), 1362-1367 (2015).